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Serum lactate dehydrogenase (LDH) is a prognostic factor for patients with stage IV melanoma. To gain insights
into the biology underlying this prognostic factor, we analyzed total serum LDH, serum LDH isoenzymes, and
serum lactate in up to 49 patients with metastatic melanoma. Our data demonstrate that high serum LDH is
associated with a significant increase in LDH isoenzymes 3 and 4, and a decrease in LDH isoenzymes 1 and 2. Since
LDH isoenzymes play a role in both glycolysis and oxidative phosphorylation (OXPHOS), we subsequently
determined using tissue microarray (TMA) analysis that the levels of proteins associated with mitochondrial
function, lactate metabolism, and regulators of glycolysis were all elevated in advanced melanomas compared with
nevic melanocytes. To investigate whether in advanced melanoma, the glycolysis and OXPHOS pathways might be
linked, we determined expression of the monocarboxylate transporters (MCT) 1 and 4. Analysis of a
nevus-to-melanoma progression TMA revealed that MCT4, and to a lesser extend MCT1, were elevated with
progression to advanced melanoma. Further analysis of human melanoma specimens using the Seahorse XF24
extracellular flux analyzer indicated that metastatic melanoma tumors derived a large fraction of energy from
OXPHOS. Taken together, these findings suggest that in stage IV melanomas with normal serum LDH, glycolysis and
OXPHOS may provide metabolic symbiosis within the same tumor, whereas in stage IV melanomas with high
serum LDH glycolysis is the principle source of energy.
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Monocarboxylate transportersIntroduction
It is now widely accepted that metabolic changes are
one of the hallmarks of cancer [1]. The widespread use
of Positron Emission Tomography (PET) imaging with
2-deoxyglucose (2-DG) uptake in several solid tumors
supports the Warburg hypothesis, which posits that
aerobic glycolysis is a major source of energy in
malignant cells [2]. However, more recently, OXPHOS
has been shown to also play a significant role in cancer
metabolism [3-5]. Previous studies have documented that
in melanoma, non-glycolytic pathways are important [6,7]* Correspondence: moschos@med.unc.edu
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reproduction in any medium, provided the orand that oxygen consumption rate, a surrogate marker for
mitochondrial respiratory chain activity, is one of the
highest in human melanoma xenografts when compared
with other tumor xenografts [8].
We recently showed by way of bioenergetics analysis
that compared with melanocytes, metastatic melanoma
cells propagated in vitro have elevated levels of OXPHOS,
in addition to glycolysis [5]. Within the three-dimensional
tumor where blood supply, and therefore oxygenation,
can be variable, it has been proposed that its center,
which is less oxygenated, is predominantly dependent on
glycolysis, whereas the more vascularized tumor periphery
is more dependent on OXPHOS. However these two
spatially distinct populations can be metabolically linked
such that lactate from the glycolytic portion of the tumor
helps fuel ATP production in the vascularized region of
the tumor through OXPHOS in a process termed
metabolic symbiosis [9,10]. However, it is presently notThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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crucial metabolic pathways in concert or sequentially.
Lactate dehydrogenase (LDH) has a central function in
cellular metabolism and is comprised of five isoforms
(LDH1-5). Each isoform is either a homotetramer (LDH1
and LDH5) or heterotetramer (LDH2, LDH3, and LDH4)
of subunits encoded by the LDHA and LDHB gene
(Additional file 1). Depending upon the LDH isoform and
the concentration of pyruvate and lactate, the enzyme can
interconvert these two compounds. More specifically,
while LDH1 and LDH2 isoforms play a major role in the
production of pyruvate from lactate, LDH4 and LDH5 are
primarily involved in the production of lactate from
pyruvate (17, 18). In the case of metastatic melanoma, it
has been known for many years that approximately 30-
40% of patients enrolled in randomized phase III clinical
trials have high serum LDH, which correlates with poor
prognosis [11]. Although to date, few randomized phase
III melanoma trials have shown clinical benefit, post-hoc
analysis of some trials, which overall were negative, did
reveal statistically significant benefits in favor of the inves-
tigational arm for melanoma patients with normal versus
high serum LDH [12-14]. The SYMMETRY study, a
randomized phase III trial that determined efficacy of the
small-molecule inhibitor Elesclomol, administered alone
or in combination with paclitaxel, provided evidence that
while the combination of Elesclomol with paclitaxel led to
significant progression-free survival (PFS) in patients with
normal serum LDH, there was a trend towards worse
overall survival (OS) in patients with high serum LDH
[15]. We [5] and others [16] have shown that Elesclomol
suppresses OXPHOS in melanoma cells in vitro, and that
melanoma cells without mitochondrial DNA (rho zero
cells) are more resistant to low-to-moderate doses of
Elesclomol. These findings, in addition to the critical role
of LDH in the interconversion of lactate and pyruvate in
the production of ATP through glycolysis or OXPHOS,
prompted us to hypothesize that differences in serum
LDH among patients with metastatic melanoma reflect
differential dependence upon these bioenergetic pathways.
In view of these observations we sought to determine
whether: 1) the LDH isoform expression profile and
levels of lactate in serum obtained from up to 49
patients with metastatic melanoma would correlate with
disease progression and OS; and 2) whether melanoma
development and progression might be linked with key
enzymes in glycolysis, OXPHOS, and lactate transport.
Our data presented herein demonstrate that patients
with advanced metastatic melanoma and high serum
LDH have low levels of LDH1 and LDH2, but elevated
levels of LDH3 and 4, suggesting that glycolysis is the
primary metabolic pathway utilized by the tumor cells in
these patients. In contrast, in patients with advanced
melanoma and normal serum LDH, OXPHOS has animportant role in addition to glycolysis for energy
production.Furthermore, our data demonstrate that
several key enzymes associated with high OXPHOS are
substantially elevated in primary and metastatic
melanomas compared with nevic melanocytes. Together
these findings support a model that both glycolysis and
OXPHOS play a significant role in developing metabolic
symbiosis in metastatic melanoma progression.
Materials and methods
Patient sera, melanoma cell lines, and tumor cell
suspensions
Sera from patients with stage IV metastatic melanoma
were obtained in compliance with University of Pittsburgh
Cancer Institute (UPCI) protocols 96–099 and 11–108.
Overall survival (OS) was defined as the interval from
collection of serum LDH, LDH isoenzyme, and serum
lactate to death from any cause. Human epidermal
melanocytes (HEMs) (Cell Applications, San Diego, CA)
were propagated in melanocyte growth medium (Cell
Applications). Human melanoma cell lines (WM983-A,
WM983-B, WM1158, WM852, Lu1205, C32) were
purchased from the Coriell Institute for Medical
Research (Camden, NJ) or the American Type Culture
Collection (Manassas, VA). The human melanoma cell
line MV3 was obtained from Dr. S. Ferrone (University of
Pittsburgh Medical Center), and the human melanoma
cell line M233 was provided by Dr. A. Ribas (UCLA).The
melanoma cell line TPF10-741, derived from a subcutane-
ous metastasis of a patient who developed secondary
resistance to the BRAF inhibitor Vemurafenib, was estab-
lished in compliance with UPCI protocol 96–099, as we
have previously reported [5]. Single-cell suspensions from
metastatic melanomas were also obtained in compliance
with UPCI protocol 96–099.
Antibodies
Antibodies used in the study were: LDHA (rabbit anti-
human polyclonal, Abcam, Cambridge, MA); LDHB
(mouse anti-human monoclonal, Sigma-Aldrich, St. Louis,
MO); MCT1 and MCT4 (rabbit anti-human polyclonal,
Chemicon, Temecula, CA); ATP synthase, H+ transport-
ing, mitochondrial F1 complex, alpha subunit 1 (ATP5A1)
(mouse anti-human monoclonal, Invitrogen, Carlsbad,
CA); hypoxia-inducible factor 1 alpha (HIF-1α) (mouse
anti-human monoclonal, BD Biosciences, San Diego, CA);
and α-tubulin (rabbit anti-human monoclonal, Cell
Signaling, Danvers MA).
Immunoblot and TMA analysis
Melanoma cell lysates were analyzed by Western blots
as previously described [17] to determine the perform-
ance of antibodies used as well as the relative expression
levels of the corresponding proteins in melanocytes and
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S2). The previously described nevus>melanoma progres-
sion TMA [18] was probed with antibody and scored as
previously described [19]. Briefly, using a 20X objective,
the bright-field image of every antibody-probed tissue
core was scored on a scale of 0 to 3+ (0 = no signal,
1+ = weak signal, 2+ = moderate signal, 3+ = strong sig-
nal). An H-score was calculated, which combined the
intensity of the antibody staining-signal with the per-
centage of cells that exhibited an antibody signal at the
different staining intensities [20]. H-scores were deter-
mined exclusively for melanoma cells.
Measurement of total serum LDH, LDH isoenzymes, and
lactate
All assays pertaining to total serum LDH, LDH isoen-
zymes, and lactate were performed by a clinical laboratory
improvement and amendment (CLIA)-certified laboratory.
This implies that, as per CLIA requirements, test results
are provided with reference ranges of upper and lower
limits of normal. More specifically, total serum LDH was
measured as routine chemistry per manufacturer’s recom-
mendations (Beckman Coulter, Inc., USA). Total serum
LDH levels are presented as the ratio of each LDH meas-
urement to the serum LDH value that is listed as the
upper limit of normal (ULN). LDH isoenzymes were iden-
tified and quantitated by agarose gel electrophoresis on
the SPIFE 2000/3000 Systems (Helena Laboratories,
Beaumont, TX) [21]. Each of the five LDH isoenzymes is
presented as percentage activity to total serum LDH
activity. For lactate measurements, samples were
maintained on ice at all times. Using lactate reagent
(lactate oxidase, peroxidase, dichlorobenzenesulfonic acid,
4-aminoantipyrine), serum lactate was determined using
the SYNCHRON Systems (Beckman Coulter, Inc., USA).
Metabolic analysis
The metabolic profile of single-cell suspensions,
prepared from ‘fresh’ metastatic melanoma tissue
specimens, was determined using a Seahorse XF24
Extracellular Flux Analyzer (Seahorse Biosciences,
Billerica, MA) and was performed on tissue specimens
within six hours of surgery to remove metastatic melan-
oma tumors in compliance with UPCI protocol 96–099.
The Seahorse Flux Analyzer provides real-time measure-
ments of oxygen consumption rate (OCR), a measure of
OXPHOS, and extracellular acidification rate (ECAR), a
measure of glycolysis [5,22]. The single-cell suspensions,
derived from four subcutaneous BRAFV600E-positive
metastatic lesions from four different patients, were
treated for 2 hr with collagenase IV (Worthington,
Lakewood NJ). The melanoma cells were then attached
for 30 minutes to tissue culture plates using Cell-Tak Cell
and Tissue Adhesive (BD Biosciences). The cells wereimmediately analyzed in the Seahorse XF24 Extracellular
Flux Analyzer under basal conditions (no treatment), and
following injection of four pharmacologic inhibitors:
Oligomycin (O) (1 μM), an inhibitor of ATP synthase,
which allows a measurement of ATP-coupled oxygen
consumption through OXPHOS; carbonyl cyanide
4-trifluoromethoxy-phenylhydrazone (FCCP) (300 nM),
an uncoupling agent that allows maximum electron trans-
port, and therefore a measure of maximum OXPHOS
respiration capacity; 2-DG (100 mM), an inhibitor of
glycolysis; and rotenone (R) (1 μM), an inhibitor of com-
plex I of the mitochondrial respiratory chain that allows a
precise measurement of mitochondrial uncoupling. All
chemicals were obtained from Sigma-Aldrich.
Statistical analysis
The R package for statistical computing software (version
2.11.1, http://www.R-project.org) was used for all statis-
tical analyses. Pearson correlation coefficients (rho, ρ)
were used to quantify the correlation between the percent-
age of each LDH isoenzymes/lactate levels and the
log-transformed serum LDH levels. Fisher’s exact tests
were used to determine possible correlations between
LDH isoenzymes/lactate levels and serum LDH levels
categorized as normal versus high. Log-rank tests were
also performed to compare the OS between patients with
high versus low total serum LDH, serum LDH isoen-
zymes, and serum lactate. Statistical analysis of the metab-
olism data was performed by one-way analysis of variance
(ANOVA) followed by the Dunnett’s test.
Kruskal-Wallis (KW) tests were used to compare the
level of expression of each molecule in the different stages
of the nevus>melanoma progression TMA. Wilcoxon
Rank-Sum tests were used to compare the expression level
between two groups. Poisson regression models were fit
to the expression level data of each molecule, and the
likelihood-ratio test (LRT) was used to test the signifi-
cance of the trend in the expression of each molecule
across different stages of the nevus>melanoma progres-
sion TMA. Spearman’s correlation coefficients were calcu-
lated to quantify the association between the various
molecules. The Bonferroni correction was used to account
for multiple comparisons.
Results
Analysis of serum LDH isoenzymes in metastatic
melanomas
Of the five tetrameric LDH isoenzymes, LDH1 and
LDH2 are preferentially associated with conversion of
pyruvate from lactate for use in OXPHOS, while LDH4
and LDH5 are involved in the production of lactate in
glycolysis (Additional file 1) [23]. The levels of serum
LDH1-5 isoenzymes and serum lactate in up to 49
patients with metastatic melanoma were determined. As
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the percentage of LDH1 was negatively associated with
the log-transformed total serum LDH level. However,
a positive association was observed between the percent-
age of LDH4 and log-transformed total serum LDH
level. In contrast, the percentage of LDH5, the most
efficient isoform in catalyzing conversion of pyruvate to
lactate, did not correlate with log-transformed serum
LDH levels. To further determine a possible correlation
between high serum LDH and high serum lactate, we
subsequently measured lactate levels in the patients’ sera.
As shown in Figure 1, panel vi, serum lactate levels show
a weak insignificant association with the log-transformed
serum LDH levels. We further categorized each of thei
iii
v
= -0.40, p= 0.006
= 0.24, p= 0.114
= 0.04, p= 0.78
Figure 1 Expression of serum LDH isoenzymes 1–5 and serum lactate
melanoma patients analyzed for total serum LDH and LDH1-5 (panels i-v) a
individual patient data showing the percentage of each LDH isoenzyme, p
absolute serum lactate levels versus log-transformed total serum LDH. Dash
of normal for each LDH isoenzyme percentage or serum lactate activity, re
serum LDH levels. All lower and upper limits of normal are based on clinica
p-values, determining the association between the percentage of each LDHLDH isoenzymes, total LDH level, and serum lactate
level into low, normal, and high levels using the clinical
cutoffs. Abnormally low levels of LDH 1 and 2 are asso-
ciated with abnormally high serum LDH level (Fisher’s
exact test p= 0.0001 and p= 0.047) and abnormally high
levels of LDH 3 and 4 are associated with abnormally
high serum LDH level (p= 0.011 and p= 0.0005). Again,
no association was detected between the high LDH5 and
high serum LDH levels. To assess whether any of the
serum LDH isoenzymes or serum lactate correlated with
OS we performed a survival analysis. At a median
follow-up of 5.8 months (range 0.07-17.8 months) 31
out of 49 patients had died. As previously shown [11],
patients with a more than 1.2-fold increase in totalii
iv
vi
= -0.16, p> 0.05
= 0.45, p= 0.001
= 0.21, p= 0.22
in patients with metastatic melanoma. Serum samples from
nd serum lactate (panel vi). Dots in each of the panels represent
resented as percentage activity to the total serum LDH activity, or
ed blue and red lines in each panel depict the lower or upper limits
spectively, whereas dashed grey lines depict normal and high total
l cutoffs. Pearson’s correlation coefficients ρ, with corresponding
isoenzyme and log-transformed total serum LDH are shown in red.
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patients with an equal or less than 1.2-fold increase in
total serum LDH (log-rank p= 0.015). Furthermore,
patients with low serum LDH1 or high serum LDH4 had
a worse OS compared with patients with normal serum
LDH1 and 4 (p= 0.057 and p= 0.019, respectively).
Expression of LDHA and HIF-1α in the nevus>melanoma
progression pathway
The detected changes in the LDH isoenzymes, and, in par-
ticular, the increase of the more glycolytic LDH isoen-
zymes (LDH3 and LDH4) along with the corresponding
decrease of the non-glycolytic LDH isoenzymes (LDH1
and LDH2), may be attributable to changes in expression
of the LDHA and LDHB subunits in melanoma cells. To
investigate whether melanoma cells express LDHA that
mediates conversion of pyruvate to lactate, we performed
immunohistochemistry studies of a nevus>melanoma pro-
gression TMA. As shown in Additional file 3 LDHA is
expressed in nevic melanocytes, and in primary and meta-
static melanomas, but its levels are higher in primary thick
melanomas. Depicted in Figure 2, panel a, are boxplots of
the TMA LDHA data, which document increased expres-
sion of LDHA with progression from nevi to advanced
melanoma (Poisson model LRT p<0.001). PairwiseLDHA
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Figure 2 LDHA and HIF-1α expression in nevi and melanomas. Boxplo
likewise, HIF-1α (panel B) H-scores of the TMA cores representing nevi, thin
(visceral and lymph node metastases). Depicted in each case is the mean o
Solid bracket lines depict significant (KW test p≤0.05), and the dashed brac
pairwise comparisons corrected for multiple comparison testing. Outliers incomparison between different stages of the nevus>mela-
noma progression pathway showed that the most signifi-
cant increase was between primary thick primary
melanomas and nevi, with the mean LDHA expression
increased approximately three-fold (Wilcoxon adjusted
p=0.003). In addition, the data also indicate trend towards
reduction between thick primary melanomas and meta-
static melanomas.
Since it has been reported that HIF-1α increases
LDHA expression [24], we also determined HIF-1α
expression in the nevus>melanoma TMA. In agreement
with the data of a previous report [25], HIF-1α was
expressed in primary melanoma tissues (Additional
file 3). Figure 2, panel b, demonstrates that HIF-1α ex-
pression increased with progression from nevi to
advanced melanoma —approximately 4-fold increase in
mean HIF-1α expression between thin primary and
metastatic melanomas, and especially lymph node me-
tastases. However, overall expression was low and some-
what heterogeneous, especially in metastatic melanoma
tissue cores (H-score < 100; Poisson model LRT
p < 0.001). The significant differences in HIF-1α expres-
sion between nevi and melanomas were consistent with
the data of an immunoblot analysis of cell lysates
obtained from cultured HEMs, the radial growth phaseH
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melanoma cell lines. In particular, HIF-1α was nearly ab-
sent in HEMs, present but at very low levels in the verti-
cal growth phase WM983-A melanoma cell line, and
various metastatic melanoma cell lines including
WM983-B, which along with the WM-983-A were
obtained from the same patient (Additional file 2).Involvement of OXPHOS in melanoma progression
We previously reported that compared with HEMs, mel-
anoma cells are more metabolically active, and in
addition to glycolysis, derive a significant proportion of
energy from OXPHOS [5]. Using a Seahorse XF24 extra-
cellular flux analyzer, which provides real-time measure-
ments of oxygen consumption rate (OCR), a marker of
OXPHOS, and extracellular acidification rate (ECAR), a
surrogate of glycolysis, we determined both the basal
rates and reserve capacity of OXPHOS in tumor cells
freshly isolated (within six hrs) from tumor biopsies
derived from four patients with metastatic melanoma.
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Figure 3 Bioenergetics analysis in single-cell melanoma suspensions,
‘fresh’ tumor respond to pharmacologic inhibitors of metabolism, as determ
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OCR and ECAR, pharmacologic inhibitors of the mito-
chondrial respiratory chain (oligomycin, FCCP, rote-
none) and of glycolysis (2-DG) were injected to
determine both the amount of ATP being derived from
OXPHOS (oligomycin-inhibitable) and the reserve cap-
acity of OXPHOS (FCCP-induced) in the tumor cells. Of
note, melanoma cells derived from this particular patient
exhibited a high reserve capacity for OXPHOS, as indi-
cated by the large increase in OCR after FCCP injection
(Figure 3A, panel i). To directly compare the data from
these four patient samples to the data derived from the
melanoma cell lines propagated in vitro, we measured
the ratio of the basal OCR (Figure 3A, panel i) to basal
ECAR (Figure 3A, panel ii), using the equation:
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However, the OCR/ECAR ratio of both freshly isolated
melanoma tumor cells and melanoma cell lines was
higher than the mean OCR/ECAR ratio of HEMs.
Together these data suggest that in tumors representing
metastatic melanomas a substantial proportion of energy
is derived from OXPHOS while HEMs propagated
in vitro have lower OXPHOS and higher glycolysis.
To obtain additional experimental evidence that
OXPHOS is elevated in melanoma cells, we used an
antibody to ATP5A1, a mitochondria-encoded subunit of
ATP synthase [26], as a ‘marker’ for OXPHOS to probe
the nevus>melanoma progression TMA. In addition, we
used an antibody to LDHB, which encodes all four subu-
nits of LDH1 that converts lactate to pyruvate. ATP5A1
expression was detected prevalently in the cytoplasm of
melanoma cells, but some expression was also seen in
tumor-interspersing macrophages and, in some cases, in
the stratum spinosum and stratum basale layer of the
epidermis (Additional file 4: Figure S4A). Like in the case
of ATP5A1, LDHB expression was detected predomin-
antly in the cytoplasm of melanoma cells (Additional
file 4). LDHB, but not ATP5A1, expression was signifi-
cantly increased in advanced melanomas compared with
nevi (Poisson model LRT p < 0.001 and p=0.098, respect-
ively). However, the mean ATP5A1 expression was
increased by at least 2.5-fold in metastatic melanomas
compared with nevi. The mean increase in LDHBATP5A1
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test p≤0.05) pairwise comparisons corrected for multiple comparison testinexpression was even higher, and, in particular between
nevi and metastatic melanomas (approximately 10-fold;
Figure 4). Given the nature of immunohistochemical ana-
lysis of TMA, we would like to point out that we could
not address whether the observed increase in ATP5A1 ex-
pression is the result of increased numbers of mitochon-
drial and/or increased numbers of components in the
mitochondrial respiratory chain of the individual mito-
chondria. However, these findings and the TMA data
described below are in agreement with the findings of our
bioenergetics studies presented herein (Figure 3) as well
as those we previously reported [5], which have shown
that mitochondrial respiration is an important biologic
feature of advanced melanomas.
Role of MCTs, indirect regulators of metabolism, in
melanoma
The data presented suggest that in addition to glycolysis,
OXPHOS is important for melanoma progression. Mouse
xenograft models have shown that cancer cells that are
located in different areas of the tumor preferentially
utilize one metabolic source over the other depending on
environmental cues [10]. Given that lactate produced by
glycolytic cells can be taken up by OXPHOS-dependent
cancer cells via MCTs under an ATP-independent passive
diffusion that follows substrate gradients and H+ trans-
port [10] it is a possibility that disrupting MCT function
might be catastrophic for cells that are dependent on0
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http://www.molecular-cancer.com/content/11/1/76glycolysis, for the reason that the cells may not be able to
release lactic acid, resulting in lowering the pH and death
[27]. Conversely, MCT inhibition may limit carbon source
supply to OXPHOS-utilizing cancer cells that are in part
dependent on lactate released by glycolytic cells for their
metabolism. In fact, a previous study suggested that tar-
geting MCT1 and 4 might be a particularly effective ap-
proach against melanoma in vivo [28]. Given the lack of
information regarding expression of MCT1 and MCT4 in
melanoma tumor tissues and the availability of highly spe-
cific small molecule MCT inhibitors, several of which are
in early clinical development (e.g. CRUKD/12/004; a
phase I study of AZD3965, an MCT1 inhibitor, in
advanced MCT1-expressing cancers), we became inter-
ested in studying the expression of MCT1 and MCT4 in
the nevus>melanoma TMA. Our TMA analysis revealed
that MCT1 expression was primarily membranous while
MCT4 expression was mostly cytoplasmic (Additional
file 5). Figure 5 demonstrates that expression of both
MCT1 and MCT4 increased with progression from nevi
to advanced melanoma (Poisson model LRT p<0.001 for
both MCT1 and MCT4). Furthermore, pairwise analysis
showed that the mean increase in MCT4 expression was
significant in both primary melanomas (thin and thick)
and metastatic melanomas compared with nevi (at least
12-fold), but not between primary and metastaticMCT1
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Figure 5 MCT1 and MCT4 expression in the nevus>melanoma TMA. T
the legends to Figures 2 and 4. Solid bracket lines show significant (KW tes
testing.melanomas. On the other hand, MCT1 expression was
elevated significantly only in metastatic melanomas when
compared with thin primary melanomas (KW p=0.036).
The immunohistochemical data are in agreement with
the data from the immunoblot analysis of MCT1 and
MCT4 expression in cultured HEMs and melanoma cell
lines (Additional file 2), which revealed lack of expression
of both MCT1 and MCT4 in HEMs, frequent expression
of MCT1 versus MCT4 in melanoma cell lines, and a
positive correlation between HIF-1α and MCT4 expres-
sion in different melanoma cell lines (MV3, WM852,
WM983-A, WM983-B, ATCC72, C32).
To explore a possible link between proteins involved
in glycolysis (LDHA, HIF-1α), OXPHOS and mitochon-
drial function (ATP5A1, LDHB), and lactate metabol-
ism and transport (LDHA, LDHB, MCT1, MCT4), we
used Pearson correlation analysis between each permu-
tation pair of the datasets of the respective proteins.
The results of this analysis (Additional file 6) revealed
a moderate (0.3<ρ≤0.42), albeit significant link (p<0.001)
between HIF-1α and LDHA, and between HIF-1α and
MCT4, but not between ATP5A1 and HIF-1α, or MCT1
and MCT4. The analysis also revealed significant asso-
ciations between OXPHOS (ATP5A1 and LDHB,
MCT1 and LDHB), glycolysis (MCT4 and LDHB), and
OXPHOS and glycolysis (LDHA and LDHB).0
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For more than two decades, 18F-2-DG has been used for
diagnostic purposes as a contrast agent for melanoma,
and high serum LDH as a prognostic factor in metastatic
melanoma [29]. However, not much is known regarding
the importance of crucial metabolic pathways in melan-
oma development and progression. With this present
study we have obtained the following novel insights.
First, we demonstrate that patients who have high serum
LDH levels have elevated levels of LDH isoenzymes,
which drive pyruvate conversion to lactate. Second,
enzymes associated with glycolysis, as well as OXPHOS,
are expressed at higher levels in primary and metastatic
melanomas than in nevi, which suggests a correlate be-
tween progression to advanced melanoma and increased
metabolic flexibility. Third, this is the first study to dir-
ectly measure the relative contribution of OXPHOS and
glycolysis in melanoma cells directly from patients,
which showed that OXPHOS plays an important role in
the generation of ATP in melanoma cells. Finally, the
data presented herein document that key regulators of
lactate transport and pH are differentially expressed in
melanomas compared with nevi.
Our finding that patients with advanced melanoma
have elevated levels of serum LDH3 and LDH4, but
reduced levels of serum LDH1 and LDH2, has also been
reported in the case of breast cancer and other solid ma-
lignancies [30,31]. However, it is not yet completely
understood what accounts for this LDH isoenzyme pat-
tern. We postulated that changes in the expression levels
of individual LDHA and B isoenzymes account for
changes in the LDH isoenzyme pattern. Data from our
nevus>melanoma progression TMA analysis, suggest
that metabolic changes in melanoma, but not in adjacent
stromal, cells might induce this differential serum LDH
isoenzyme profile. This conclusion is based on the find-
ing that LDHA was elevated in primary melanomas
compared with nevi, and was even more elevated in
thick (Breslow thickness of invasion > 2 mm) primary
melanomas. In addition, the significant correlation be-
tween LDHA and HIF-1α expression we detected in our
TMA analysis is in agreement with previous studies,
which showed that HIF-1α increases glycolytic metabol-
ism, including the upregulation of LDHA [24]. The ab-
sence of increased LDH5 in patients with high serum
LDH can be explained by the significant positive correl-
ation between LDHA and LDHB expression in melano-
mas (Additional file 6) and that more LDHB than
LDHA proteins are upregulated in advanced melanomas
(Figures 2 and 4). The lower expression of LDH5 in
metastatic compared with thick primary melanoma can
be explained by intra-tumor heterogeneity in advanced
melanoma cases in terms of reliance of melanoma cells
to glycolysis versus OXPHOS. In other words, severaltumor cores that comprised this TMA may have been
obtained from specific regions of the tumor that were
metabolically dissimilar. In fact, one third of the tumor
cores were derived from lymph node metastatic melan-
oma. Unfortunately, the lack of clinicopathologic anno-
tation makes it impossible to address the significant
variability in LDHA expression seen in metastatic
melanoma.
We [5] and others [32] have previously found that in
the case of melanoma, OXPHOS plays an important role
in the cells’ metabolism in addition to glycolysis in vitro.
Data from our study including: 1) the bioenergetics ana-
lysis in melanoma cells derived directly from patients; 2)
the immunohistochemical analysis of ATP5A1, a key
regulatory component of the mitochondrial respiratory
chain; and 3) high expression of LDHB, a key enzyme
that converts lactate to pyruvate, all support the import-
ance of OXPHOS in melanoma. These data, which are
in agreement with two previous reports in melanoma
[8,33] do not necessarily refute the Warburg hypothesis
that cancer cells rely heavily upon glycolysis for energy
production [2]. Instead, our data strongly suggest that
the metabolically flexibility of melanoma cells can pro-
vide selective advantage for tumor cell survival in diverse
environments with low oxygen tension, scarce carbon
source availability, and low pH [9].
In melanoma, monocarboxylate transporters should be
added to the increasing complexity of cancer metabolism
resources/pathways, which include glycolysis, reductive
carboxylation of glutamine [6,34], and OXPHOS [5].
MCT1 and MCT4 play an important role in the trans-
port of carbon sources among cancer cells in relation to
environmental cues, such as pH and oxygen tension.
The observed significant upregulation of MCT4, the
principal transporter for lactate efflux [35] in melanomas
compared with nevi may reflect conditioning of melan-
oma cells to high rates of lactate production that must
be exported out of cells for survival. Our data point to a
positive correlation between the immunohistochemical
expression of MCT4 and HIF-1α and MCT4 and LDHA,
which is in agreement with previous reports that MCT4
is a downstream effector of HIF-1α [36]. Together these
data suggest that MCT4 may be expressed by the frac-
tion of melanoma cells in the tumor that predominantly
utilizes glycolysis for energy production and may be a
critical therapeutic target.
The lack of substantial upregulation of serum lactate
levels in patients with high serum LDH raises the ques-
tion whether the lactate that is produced by glycolytic
melanoma cells is taken up by metabolically symbiotic
tumor cells deriving their energy from OXPHOS before
reaching the systemic circulation, which is in support of
this metabolic symbiosis model. These data are also in
agreement with a previous report, which showed that
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regulate their access to energy metabolites [10]. Our
study also suggests that advanced melanomas become
glycolytic due to their hypoxic state, which might be
linked to hypoxia-induced stabilization of HIF-1α activ-
ity. Although HIF-1α regulates the glycolytic program, it
also suppresses OXPHOS [37]. Based upon our data and
those of a previously published study [10], we depict a
cartoon (Figure 6) that serves to illustrate a workingB
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vent buildup of acid that may prevent tumor growth
(MCT4 upregulation). In metastatic melanomas with
normal serum LDH, balanced reliance on both
OXPHOS and glycolysis is in place until the tumors
grow beyond a certain size and thereupon, hypoxic
regions develop (metastatic melanomas with high serum
LDH). At this point in tumor progression, three distinct
melanoma cell populations evolve: one that resides in
extremely hypoxic areas, is necrotic, and releases
glycolytic LDH isoenzymes (LDH3, 4), which is the
primary cause for increased serum LDH. The second
melanoma cell population resides in hypoxic areas, upre-
gulates the HIF-1α glycolytic program, and releases lactate
and hydrogen ions to maintain normal pH. The third
population is in well-oxygenated areas and dependent
upon OXPHOS by metabolizing glucose as well as lactate,
which is released from the nearby glycolytic melanoma
cell population. The mechanism(s) that tip(s) the balance
towards more glycolysis and less OXPHOS in advanced
melanoma are unclear, but may involve, as Otto Warburg
described, mitochondrial dysfunction. This loss in
mitochondrial function may be “functionally reversible”
(i.e. hypoxia) or “permanently irreversible” (i.e. mutations
in the mitochondrial DNA that encode for components of
the mitochondrial respiratory chain) [38,39].
Finally, we believe that the findings of our study may
be of relevance with respect to the design of future mel-
anoma trials. First, the association of low LDH1 isoen-
zyme levels, in addition to high LDH4 levels with OS in
patients with high serum LDH implies that changes in
the reliance of both OXPHOS and glycolysis, but not
only glycolysis alone, are clinically important. Therefore,
agents that attempt to revert the reliance of cancer cells
more on OXPHOS and less on glycolysis may be clinic-
ally effective [40]. Second, since serum LDH levels define
two different metastatic melanoma subgroups, one with
normal serum LDH levels that is primarily dependent
upon OXPHOS and the other with high serum LDH
that is predominantly comprised of cells that are
dependent upon OXPHOS, therapies that only disrupt
OXPHOS may only have an effect in patients with
normal serum LDH [5]. One such therapy is Elesclomol
that we [5] and others [16] have shown to suppress
OXPHOS by disrupting components of the mitochon-
drial respiratory chain that was previously shown to have
an opposite clinical effect in patients with metastatic
melanoma and normal versus high serum LDH [15]. On
the other hand, patients with high serum LDH bear
melanomas with hypoxic areas that produce high
HIF-1α levels which upregulate components of the
glycolytic pathway in addition to components of the
angiogenesis pathway, such as the vascular endothelial
growth factor. These tumors are expected to be moreprone to glycolysis inhibitors, yet to be identified, as well
as to angiogenesis inhibitors, such as bevacizumab, as
previously described [14]. The findings of our study also
suggest that MCT4, which transports lactate from glyco-
lytic cells, has an important, and most likely, equally im-
portant role alongside MCT1. However, targeting MCT4
may clinically be more effective when melanomas become
MCT1 independent, or when targeted in combination with
MCT1 to prevent resistance to treatment [41].
Additional files
Additional file 1: Figure S1. Schematic presentation of LDH1-5 and
their involvement in OXPHOS and glycolysis. Red circles indicate LDHA
subunits and blue circles indicate LDHB subunits.
Additional file 2: Figure S2. Validation of antibodies used in the
nevus-melanoma TMA analyses. Immunoblot analysis of whole cell
lysates, prepared from HEMs and different melanoma cell lines were
probed with antibody specific for MCT4, MCT1, HIF-1α, LDHB, LDHA. α-
tubulin served as loading control.
Additional file 3: Figure S3. LDHA and HIF-1α expression in nevi and
melanomas. (A-B, panels a) TMA cores comprised of nevi, and primary
and metastatic melanoma tissue core, probed with antibody to LDHA or
HIF-1α, and counterstained with hematoxylin. (A-B, panels b) 10X
magnification of select TMA cores.
Additional file 4: Figure S4. ATP5A1 and LDHB expression in nevi and
melanomas. (A-B, panels a) TMA cores comprised of nevi, primary
melanoma, and metastatic melanoma, probed with antibody to ATP5A1
or LDHB, and counterstained with hematoxylin. (A-B, panels b) 10X
magnification of select TMA cores.
Additional file 5: Figure S5. MCT1 and MCT4 expression in the
nevus>melanoma TMA. The TMA study was performed as described in
the legends to Additional files 3 and 4: Figures S3 and S4.
Additional file 6: Figure S6. Pairwise correlation matrix analysis of
expression of the various molecules in the nevus>melanoma TMA.
Depicted in the lower left corner are dot plots of the H-scores between
each permutation pair of the dataset of the six proteins whose
expression was determined in the TMA. Shown in the upper right corner
are Spearman rank correlation coefficients with corresponding p-values
for the respective permutation pair of the six proteins. Rho and p values
showing significant association are highlighted, and/or presented in a
larger font size. Green-colored boxes in the matrix depict expected and
known significant associations, blue-colored boxes show known
insignificant associations, and red-colored boxes denote novel and
significant associations.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JH, SJM, and LMD performed immunohistochemical analysis of the nevus-
melanoma TMAs. MBM and GV performed Seahorse analysis of melanoma
cell lines and tumor tissues. GV established melanocytes and melanoma cell
cultures and immunoblot analysis for each of the antibodies used for
immunohistochemical analysis. ST, GV, MBM performed in vivo imaging of
glycolysis of human melanoma xenografts that supported the notion of
metabolic symbiosis (data not shown). YL and LHM performed analysis of
serum LDH and immunohistochemical data. SJM and JMK provided patient
samples (sera and tumor tissues). ST, JMK, DB, BVH and SJM analyzed all
experiments and wrote the manuscript. All authors read and approved the
final manuscript.
Acknowledgements
We would like to thank D. Bachorski for collecting sera for LDH and lactate
studies, M. Acquafondata for antibody probing of the TMA. This work was
Ho et al. Molecular Cancer 2012, 11:76 Page 12 of 13
http://www.molecular-cancer.com/content/11/1/76supported by a Career Development Award to S. J. M. from the NIH
P50CA121973 SPORE in Skin Cancer, and a Pennsylvania Department of
Health PA CURE award to B. V. H.
Author details
1Department of Dermatology, University of Pittsburgh, Pittsburgh, PA 15213,
USA. 2Departments of Pharmacology and Chemical Biology, University of
Pittsburgh, Pittsburgh, PA 15213, USA. 3Department of Biostatistics, University
of Pittsburgh, Pittsburgh, PA 15213, USA. 4Department of Medicine,
University of Pittsburgh, Pittsburgh, PA 15213, USA. 5Department of Surgery,
University of Pittsburgh, Pittsburgh, PA 15213, USA. 6Department of
Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
7Department of Pathology, University of Pittsburgh, Pittsburgh, PA 15213,
USA. 8Present Address: Clinical Associate Professor, Department of Medicine,
University of North Carolina at Chapel Hill Physicians Office Building, 3rd
Floor, Suite 3116, CB #7305, 170 Manning Drive, Chapel Hill, NC 27599, USA.
Received: 5 March 2012 Accepted: 1 October 2012
Published: 9 October 2012References
1. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation.
Cell 2011, 144:646–674.
2. Warburg O: On the origin of cancer cells. Science 1956, 123:309–314.
3. Elia U, Flescher E: Combined Chemotherapy or Biotherapy with
Jasmonates: Targeting Energy Metabolism for Cancer Treatment.
Curr Pharm Biotechnol 2012, Jun 1. [Epub ahead of print].
4. Rodríguez-Enríquez S, Gallardo-Pérez JC, Marín-Hernández A, Moreno-
Sánchez R: The Warburg Hypothesis and the ATP Supply In Cancer Cells
Is Oxidative Phosphorylation impaired in malignant neoplasias?
Curr Pharm Biotechnol 2012, Jun 1. [Epub ahead of print].
5. Barbi de Moura M, Vincent G, Fayewicz SL, Bateman N, Hood BL, Sun M,
Suhan J, Duensing S, Yin Y, Sander C, et al: Mitochondrial Respiration - an
Important Therapeutic Target in Melanoma. PLoS One 2012, 7(8):e40690.
6. Scott DA, Richardson AD, Filipp FV, Knutzen CA, Chiang GG, Ronai ZA,
Osterman AL, Smith JW: Comparative metabolic flux profiling of
melanoma cell lines: beyond the Warburg effect. J Biol Chem 2011,
286:42626–42634.
7. Qin JZ, Xin H, Nickoloff BJ: Targeting glutamine metabolism sensitizes
melanoma cells to TRAIL-induced death. Biochem Biophys Res Commun
2010, 398:146–152.
8. Kallinowski F, Schlenger KH, Runkel S, Kloes M, Stohrer M, Okunieff P, Vaupel
P: Blood flow, metabolism, cellular microenvironment, and growth rate
of human tumor xenografts. Cancer Res 1989, 49(14):3759–3764.
9. Nakajima EC, Van Houten B: Metabolic symbiosis in cancer: Refocusing
the Warburg lens. Mol Carcinog 2012, Jan 6: doi 10.1002/mc.21863.
[Epub ahead of print].
10. Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De
Saedeleer CJ, Kennedy KM, Diepart C, Jordan BF, et al: Targeting lactate-fueled
respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 2008,
118:3930–3942.
11. Manola J, Atkins M, Ibrahim J, Kirkwood J: Prognostic factors in metastatic
melanoma: a pooled analysis of Eastern Cooperative Oncology Group
trials. J Clin Oncol 2000, 18:3782–3793.
12. Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E, Gonzalez
R, Hersh E, Feun L, Belt R, et al: Results from a randomized phase III study
comparing combined treatment with histamine dihydrochloride plus
interleukin-2 versus interleukin-2 alone in patients with metastatic
melanoma. J Clin Oncol 2002, 20:125–133.
13. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick
AC, DeConti R, Hersh EM, Hersey P, et al: Bcl-2 antisense (oblimersen
sodium) plus dacarbazine in patients with advanced melanoma: the
Oblimersen Melanoma Study Group. J Clin Oncol 2006, 24:4738–4745.
14. Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF,
Weber JS, Nguyen H, Cheverton P, Chen D, et al: BEAM: a randomized
phase ii study evaluating the activity of bevacizumab in combination
with carboplatin plus paclitaxel in patients with previously untreated
advanced melanoma. J Clin Oncol 2012, 30:34–41.
15. Hauschild A, Eggermont AM, Jacobson E, O'Day SJ: Phase III, randomized,
double-blind study of elesclomol and paclitaxel versus paclitaxel alonein stage IV metastatic melanoma (LBA9012) [abstract]. J Clin Oncol 2009,
27:18s.
16. Blackman RK, Cheung-Ong K, Gebbia M, Proia DA, He S, Kepros J, Jonneaux
A, Marchetti P, Kluza J, Rao PE, et al: Mitochondrial electron transport is
the cellular target of the oncology drug elesclomol. PLoS One 2012,
7:e29798.
17. Moschos SJ, Dodd NR, Jukic DM, Fayewicz SL, Wang X, Becker D: Suppressing
the high-level expression and function of ATM in advanced-stage
melanomas does not sensitize the cells to ionizing radiation. Cancer Biol
Ther 2009, 8:1815–1825.
18. Nazarian RM, Prieto VG, Elder DE, Duncan LM: Melanoma biomarker
expression in melanocytic tumor progression: a tissue microarray study.
J Cutan Pathol 2010, 37(Suppl 1):41–47.
19. Moschos SJ, Jukic DM, Athanassiou C, Bhargava R, Dacic S, Wang X, Kuan SF,
Fayewicz SL, Galambos C, Acquafondata M, et al: Expression analysis of Ubc9,
the single small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in
normal and malignant tissues. Hum Pathol 2010, 41:1286–1298.
20. Detre S, Saclani Jotti G, Dowsett M: A "quickscore" method for
immunohistochemical semiquantitation: validation for oestrogen
receptor in breast carcinomas. J Clin Pathol 1995, 48:876–878.
21. Hsu MY, Kohler MM, Barolia L, Bondar RJ: Separation of five isoenzymes of
serum lactate dehydrogenase by discontinuous gradient elution from a
miniature ion-exchange column. Clin Chem 1979, 25:1453–1458.
22. Qian W, Van Houten B: Alterations in bioenergetics due to changes in
mitochondrial DNA copy number. Methods 2010, 51:452–457.
23. Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P: Anticancer
targets in the glycolytic metabolism of tumors: a comprehensive review.
Front Pharmacol 2011, 2:49.
24. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P,
Giallongo A: Hypoxia response elements in the aldolase A, enolase 1,
and lactate dehydrogenase A gene promoters contain essential binding
sites for hypoxia-inducible factor 1. J Biol Chem 1996, 271:32529–32537.
25. Valencak J, Kittler H, Schmid K, Schreiber M, Raderer M, Gonzalez-
Inchaurraga M, Birner P, Pehamberger H: Prognostic relevance of hypoxia
inducible factor-1alpha expression in patients with melanoma. Clin Exp
Dermatol 2009, 34:e962–e964.
26. Yusenko MV, Ruppert T, Kovacs G: Analysis of differentially expressed
mitochondrial proteins in chromophobe renal cell carcinomas and renal
oncocytomas by 2-D gel electrophoresis. Int J Biol Sci 2010, 6:213–224.
27. Neri D, Supuran CT: Interfering with pH regulation in tumours as a
therapeutic strategy. Nature Rev Drug Discov 2011, 10:767–777.
28. Wahl ML, Owen JA, Burd R, Herlands RA, Nogami SS, Rodeck U, Berd D,
Leeper DB, Owen CS: Regulation of intracellular pH in human melanoma:
potential therapeutic implications. Mol Cancer Ther 2002, 1:617–628.
29. Finck SJ, Giuliano AE, Morton DL: LDH and melanoma. Cancer 1983,
51:840–843.
30. Khurana P, Tyagi N, Salahuddin A, Tyagi SP: Serum lactate dehydrogenase
isoenzymes in breast tumours. Indian J Pathol Microbiol 1990, 33:355–359.
31. Giannoulaki EE, Kalpaxis DL, Tentas C, Fessas P: Lactate dehydrogenase
isoenzyme pattern in sera of patients with malignant diseases. Clin Chem
1989, 35:396–399.
32. Xu K, Mao X, Mehta M, Cui J, Zhang C, Xu Y: A Comparative Study of
Gene-Expression Data of Basal Cell Carcinoma and Melanoma Reveals
New Insights about the Two Cancers. PLoS One 2012, 7:e30750.
33. Berridge MV, Tan AS: Effects of mitochondrial gene deletion on
tumorigenicity of metastatic melanoma: reassessing the Warburg effect.
Rejuvenation Res 2010, 13(2–3):139–141.
34. Filipp FV, Scott DA, Ronai ZA, Osterman AL, Smith JW: Reverse TCA cycle
flux through isocitrate dehydrogenases 1 and 2 is required for
lipogenesis in hypoxic melanoma cells. Pigment Cell Melanoma Res 2012,
25:375–383.
35. Dimmer KS, Friedrich B, Lang F, Deitmer JW, Broer S: The low-affinity
monocarboxylate transporter MCT4 is adapted to the export of lactate
in highly glycolytic cells. Biochem J 2000, 350(Pt 1):219–227.
36. Ullah MS, Davies AJ, Halestrap AP: The plasma membrane lactate
transporter MCT4, but not MCT1, is up-regulated by hypoxia
through a HIF-1alpha-dependent mechanism. J Biol Chem 2006,
281:9030–9037.
37. Fukuda R, Zhang H, Kim JW, Shimoda L, Dang CV, Semenza GL:
HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of
respiration in hypoxic cells. Cell 2007, 129:111–122.
Ho et al. Molecular Cancer 2012, 11:76 Page 13 of 13
http://www.molecular-cancer.com/content/11/1/7638. de Moura MB, dos Santos LS, Van Houten B: Mitochondrial dysfunction in
neurodegenerative diseases and cancer. Environ Mol Mutagen 2010,
51:391–405.
39. Mazure NM, Brahimi-Horn MC, Pouyssegur J: Hypoxic mitochondria:
accomplices in resistance. Bull Cancer 2011, 98:40–46.
40. Hendifar AE, Chawla SP, Quon D, Chua VS, Fernandez L, Nagre S, Okunnu M,
Chmielowski B, Singh AS, Akmaev S, et al: Phase I study of BPM 31510 in
advanced solid tumors: Updated analysis of a novel treatment with
promising activity [abstr 3015]. J Clin Oncol 2012, 27.
41. Le Floch R, Chiche J, Marchiq I, Naiken T, Ilk K, Murray CM, Critchlow SE,
Roux D, Simon MP, Pouyssegur J: CD147 subunit of lactate/H+ symporters
MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth
of glycolytic tumors. Proc Natl Acad Sci USA 2011, 108:16663–16668.
doi:10.1186/1476-4598-11-76
Cite this article as: Ho et al.: Importance of glycolysis and oxidative
phosphorylation in advanced melanoma. Molecular Cancer 2012 11:76.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
